Health News Releases

June 09, 2014 13:45

Quintiles Honored for IT Innovation, Named to 2014 CIO 100

Quintiles, the world’s largest biopharmaceutical services provider, has been named to the 2014 CIO 100. Each year, CIO magazine identifies and honors 100 organizations that have distinguished themselv

June 09, 2014 11:05

Quintiles Executive to Present at the 2014 Wells Fargo Healthcare Conference

Quintiles CFO Kevin Gordon will present at the 2014 Wells Fargo Healthcare Conference on Tuesday, June 17, 2014, in Boston’s InterContinental Hotel. The Quintiles presentation will begin at 1:10 p.

June 05, 2014 18:15

EMA accepts marketing authorisation application for nintedanib* in IPF

For non-US health media only Boehringer Ingelheim today announced that the application for marketing authorisation of nintedanib*, a tyrosine kinase inhibitor (TKI), for the treatment of idiopathic

June 05, 2014 16:30

New Study Reported Prevena™ Therapy Patients Had a Significantly Lower Infection Rate Following Cardiac Surgery Compared to Control Group

Kinetic Concepts, Inc. (www.kci1.com/KCI1/home) announced today that a new study, published in the International Wound Journal, showed the Prevena™ Incision Management System used over closed incision

June 03, 2014 21:05

Eppendorf Announces New BioBLU® 5c and 14c Adaptor Kits

Eppendorf is proud to announce a new addition to the BioBLU Single-use Vessel Adaptor Kit portfolio. The BioBLU 5c and 14c Adaptor Kits allow BioBLU 5c and 14c Single-use vessels to be used on and con

June 03, 2014 21:00

Pathway Genomics Launches BRCA1/2 Genetic Test with One for One Program

Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, today announced it has launched BRCATrueTM, a next-generation

June 03, 2014 11:45

New data show Giotrif® (afatinib) provided more than one year additional survival for lung cancer patients with the most common type of EGFR mutation (del19) compared to chemotherapy

For Ex-US and Ex-UK Media only Boehringer Ingelheim today announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LU

June 03, 2014 11:35

Quintiles Named to the Fortune 500

Quintiles, the world’s largest biopharmaceutical services provider, has been named to the Fortune 500 (http://goo.gl/nKpkC6) list of largest U.S. companies ranked by revenue. “Being named to the Fo

June 02, 2014 10:15

Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014

Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of

May 29, 2014 10:30

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation

For media outside of the U.S., the UK & Canada only Boehringer Ingelheim announced today that the company has reached a comprehensive settlement of state and federal cases in the U.S. litigation re

May 28, 2014 16:50

Quintiles CEO Tom Pike to Present at Goldman Sachs 35th Annual Global Healthcare Conference

Quintiles CEO Tom Pike will present at the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014 at the Terranea Resort in Rancho Palos Verdes, CA. The Quintiles presen

May 28, 2014 16:40

Octapharma sponsors symposium “Spotlight on the human factor: building a foundation for the future of haemophilia A management

Octapharma sponsored the symposium “Spotlight on the human factor: building a foundation for the future of haemophilia A management” during the World Federation of Hemophilia (WFH) World Congress in M

May 27, 2014 21:05

Eppendorf Announces New BioBLU® 50c Single-use Vessel Adaptor Kits

Eppendorf is proud to announce the brand new line of BioBLU 50c Single-use Vessel Adaptor Kits. These convenient adaptor kits allow a 40 L single-use vessel to be used on existing bench-scale controll

May 27, 2014 09:40

European Medicines Agency (EMA) adopts positive opinion on Octapharma’s human cell line recombinant human FVIII (Nuwiq®) in children and adults with haemophilia A

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authoris

May 23, 2014 17:20

Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin)

For Non-U.S. and Non-U.K. Media The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli L

May 23, 2014 13:20

Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients

For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announces the next step in the clinical development of idarucizumab*, the investigational antidote for rapid reversal

May 23, 2014 10:55

Covidien Releases Two-Year Study Results Demonstrating Sustained Effectiveness of Drug-Coated Angioplasty Balloon Technology

Covidien’s (www.covidien.com) Stellarex™ drug-coated angioplasty balloon (Stellarex DCB) continues to be shown as safe and effective for treatment of peripheral arterial disease (PAD), according to ne

May 22, 2014 20:00

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

During the Late Breaking Clinical Trial sessions at EuroPCR yesterday and published simultaneously in the European Heart Journal, Professor Uwe Zeymer of Klinikum Ludwigshafen, Ludwigshafen, Germany a

May 22, 2014 18:08

South-South Cooperation to Improve Diabetes Care

China, Zimbabwe and Ecuador will have an exclusive opportunity to replicate and adapt a successful diabetic foot care project originally developed in Alexandria, Egypt. This pioneering partner approac

May 22, 2014 15:25

COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone

For media outside of the US, the UK & Canada only Boehringer Ingelheim today announced the first Phase III data for the once-daily fixed-dose combination of tiotropium and olodaterol. Results from

May 20, 2014 15:35

Pulmonx Announces First Comprehensive Report of Collateral Ventilation Assessed by the Chartis Endobronchial Catheter in Late Stage Emphysema

Pulmonx (www.pulmonx.com/us-or-international), an emerging leader in interventional pulmonology, announced today that multiple clinical abstracts examining the diagnostic and therapeutic utility of it

May 20, 2014 10:55

Quintiles Executive to Present at Jefferies 2014 Global Healthcare Conference

Quintiles CFO Kevin Gordon will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 in New York City at the Grand Hyatt New York. The Quintiles presentation will beg

May 19, 2014 17:50

Ferring launches Guts4life, An Interactive Online Resource for People with Inflammatory Bowel Disease

Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (www.guts4life.com), a new interactive website with information, support and inspiration for people concerned with C

May 19, 2014 10:35

IPF Phase III results published in NEJM show nintedanib* slows disease progression

For non-US health media only Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib* significantly slowed disease progression in

May 15, 2014 20:05

Neos Therapeutics Announces Issuance of New Patent Covering Composition of Matter for Company’s Novel ADHD Products

Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled re

News by Region

News by Industry